DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for erythema multiforme — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleErythema multiforme maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for erythema multiforme is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
nuclear receptor subfamily 3 group C member 1 (NR3C1) — NR3C1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet adpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7KW7 · 3.57 Å · ligand ADENOSINE-5'-DIPHOSPHATE (ADP). Experimental structure, not a prediction.
What the evidence adds up to
Erythema multiforme is an acute, self-limiting hypersensitivity reaction that ranges from a mild cutaneous variant with minimal oral involvement to a severe variant with extensive mucocutaneous epithelial necrosis, which can lead to mortality. There are no specific diagnostic tests; diagnosis is mainly clinical. Three forms are described: minor, major, and oral erythema multiforme. The condition presents a diagnostic dilemma due to varied possible manifestations. A 2020 case series reports different aetiological spectrums. A 2022 article reports 5 cases of different forms following drug administration.
A 1992 report describes a young woman who developed erythema multiforme in association with multiple patch test reactions. Sequential patch testing revealed 2 true positive reactions (colophony and fragrance mix) and was not associated with a flare of erythema-multiforme-type lesions. The authors note that development of erythema multiforme should be included in the list of possible adverse reactions to patch testing, albeit a rare occurrence.
Knowing the aetiological spectrum is described as key for management. The 2020 paper states that in some cases erythema multiforme leads to mortality, but no specific survival or response rates are given in any of these abstracts. No concrete numbers on sample sizes beyond the single case and the series of 5 cases are provided.
What is still missing: no controlled trials of any treatment are reported; no patient stratification by aetiology (infection versus drug) has been tested in a prospective design; no funding for such trials is mentioned.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Contact Dermatitis · 1992 · 19 citations
Erythema multiforme reaction to patch testing
AbstractA young woman developed erythema multiforme in association with multiple patch test reactions. Sequential patch testing revealed 2 true positive reactions (colophony and fragrance mix), and was not associated with flare of erythema-multiforme-type lesions. The development of erythema multiforme should be included in the list of possible adverse reactions to patch testing, albeit a rare occurrence.
Pan African Medical Journal · 2020 · 5 citations · open access
Erythema Multiforme: integrating the superfluous diagnosis to a veracious conclusion
AbstractErythema multiforme (EM) is an acute, self-limiting hypersensitivity reaction that ranges from a mild cutaneous, exanthematous variant with minimal oral involvement to a progressive fulminating severe variant with extensive mucocutaneous epithelial necrosis (SJS & TEN). Knowing the etiological spectrum is the key for management in EM where sometimes leads to mortality. There are no specific diagnostic tests for EM, diagnosis is mainly clinically supported. Here in we report series of cases of EM with different etiological spectrum.
Journal of Morphological Sciences · 2022 · 1 citations · open access
ORAL ERYTHEMA MULTIFORME – CASE REPORTS, DIAGNOSTIC AND TREATMENT DILEMMA
AbstractErythema multiforme is acute mucocutaneous condition that is considered to be immune- mediated hypersensitivity reaction to medicine or an infection. There are described three forms of erythema multiforme: “minor form”, “major form” and oral erythema multiforme. It presents a diagnostic dilemma due to varied possible manifestations. Diagnosis is often made based on history and clinical examination. In this article we report 5 cases of different forms of erythema multiforme following drug administration. Keywords: erythema multiforme, drug induced.
A Case Report on an Elusive Incident of Erythema Multiforme
AbstractThe presentation of erythema multiforme in the emergency department is relatively rare, thus recognition and rapid intervention requires a high index of suspicion. This study presents a case of a 55-year-old female with past medical history of hypertension and active endometrial cancer with recent chemotherapy treatment complaining of four days of progressive erythematous rash with associated pruritis and blistering. An exam found multiple tense, scattered vesicles with an erythematous base. The patient also demonstrated leukopenia, elevated alkaline phosphatase level, and elevated C-reactive protein level. A shave biopsy was performed and intravenous acyclovir was started for concern of varicella-zoster virus. Biopsy results favored an erythema multiforme diagnosis, and she was discharged with topical clobetasol. In addition to reviewing the presentation and intervention of erythema multiforme, this case report adds to growing literature of erythema multiforme as a delayed reaction to malignancy therapy. Topics: Erythema multiforme, dermatology, radiotherapy.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
